The Epidemiology of Diabetes and Cancer
- 732 Downloads
The literature on cancer occurrence in persons with diabetes has almost invariably been concerned with relative measures. In this paper, we briefly review this, but the aim is to quantify the absolute occurrence of diabetes and cancer in the population in order to give a fuller picture, which also includes the competing mortality risk. Overall, we find that some 35 % of the population will have a diagnosis of diabetes in their lifetime, 44 % a diagnosis of cancer, and about 15 % will have both diagnoses. The impact of differing mortality between persons with and without diabetes is illustrated by the fact that a person without diabetes at age 50 has a smaller lifetime risk of cancer than a person aged 50 with diabetes. Thus, the differences in cancer occurrence between persons with and without diabetes are of quantitatively smaller importance than the differences in mortality.
KeywordsDiabetes and cancer Epidemiology Demography Lifetime risk of diabetes and cancer Absolute risk of diabetes
Compliance with Ethics Guidelines
Conflict of Interest
Bendix Carstensen and Marit Eika Jørgensen are employees of Steno Diabetes Center, a research Hospital owned by Novo Nordisk and operating as part of the Danish National Health Service. Bendix Carstensen and Marit Eika Jørgensen own shares in Novo Nordisk.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 8.••Andersson C, Vaag A, Selmer C, Schmiegelow M, Sørensen R, Lindhardsen J, et al. Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open 2012; 2(3). The only study which comprises the entire population in evaluation of possible drug effects on cancer occurrence in persons with diabetes, and therefore the only study of drug effects not potentially biased by selection of subgroups of patients. The study only analyses occurrence of all cancers, not specific sites of cancer. It shows that the risk of cancer is elevated shortly after initiation of (any) therapy, but not in the long run. Google Scholar
- 9.•Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012;55(4):948–58. The largest study of cancer occurrence among persons with diabetes. The study takes duration of diabetes into account and shows that risk is highest shortly after diagnosis of diabetes. Also includes analysis by cancer site and insulin use.PubMedCrossRefGoogle Scholar
- 10.•Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011;54:2263–71. The first study to systematically include duration of diabetes as an important determinant of the cancer risk among persons with diabetes. Shows that the risk of cancer is highest shortly after diagnosis of cancer, and inversely related to frequency of GP contact before diabetes diagnosis.PubMedCrossRefGoogle Scholar
- 21.•Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG, et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012;55(6):1607–18. This paper discusses the methodological aspects of epidemiological evaluation of cancer risk in persons with and without diabetes, and proposes guidelines for this type of studies, particularly in relation to possible drug effects.PubMedCrossRefGoogle Scholar